Venlafaxine: Discovery, Development, Safety and Pharmacovigilance
Venlafaxine is an antidepressant whose clinical usefulness and safety challenges are both shaped by inhibition of monoamine reuptake. It offers an alternative to selective serotonin reuptake inhibitors (SSRIs), but its extended-release formulations, active metabolite, dose-dependent noradrenergic effects and susceptibility to discontinuation symptoms create distinct questions for clinicians and pharmacovigilance assessors. A suspected adverse reaction must be interpreted in the context of the precise formulation, dose trajectory, concomitant medicines, illness course and timing of missed or stopped doses. [1,2]
- Venlafaxine: Discovery, Development, Safety and Pharmacovigilance
- Discovery and development: a changing antidepressant landscape
- Pharmacology and exposure
- Evidence of benefit and its boundaries
- Safety profile: mechanisms, clinical phenotypes and risk management
- Product-specific listedness and jurisdictional comparison
- Special populations and clinical context
- Practical pharmacovigilance: from report to evidence
- Figure assessment
- Key takeaways
- References
- Regulatory Note
Discovery and development: a changing antidepressant landscape
Wyeth's programme and the move beyond selective serotonin reuptake
Venlafaxine was developed in Wyeth's antidepressant programme during a period when monoamine-reuptake pharmacology was being translated into agents with different receptor-binding and tolerability profiles from older tricyclic antidepressants. The historical development story is important because the immediate-release tablet and extended-release capsule were not identical products in their dosing convenience or trial evidence. Wyeth's contemporaneous corporate disclosures identify the immediate-release product, Effexor, as marketed in the United States from March 1994, followed by the controlled-release Effexor XR formulation in 1997. A historical FDA approval record independently documents the 1997 extended-release application. [3,4]
This chronology should not be confused with a claim that the two formulations are pharmacologically different active substances. Both deliver venlafaxine; formulation changes the concentration–time profile and administration instructions. The original sponsor's clinical programme and later generic entry distributed safety responsibility across multiple marketing-authorisation holders. For a real case, the manufacturer, brand, strength, release characteristics and batch where available are more useful than assuming all venlafaxine products share one unchanged label. [1,2]
Development of indications
The clinical programme progressed from major depressive disorder to anxiety disorders, with US extended-release prescribing information covering major depressive disorder (MDD), generalised anxiety disorder (GAD), social anxiety disorder and panic disorder. These are product- and jurisdiction-specific indications, not a worldwide statement about every immediate-release or extended-release formulation. The US initial-approval history of the extended-release product dates to 1997, while individual generic labels and their subsequent revisions require separate identification. [1]
The commercial transition from originator products to generics is relevant to traceability, not evidence that one manufacturer's product has a superior safety profile. The emergence of modified-release preparations also complicates medication-error surveillance: a substitution or dispensing error may alter dosing frequency, adherence and withdrawal risk even when the active substance name remains unchanged.
Pharmacology and exposure
Serotonin and noradrenaline reuptake
Venlafaxine and its active metabolite O-desmethylvenlafaxine inhibit neuronal serotonin and noradrenaline uptake. At clinically used lower doses, serotonergic effects predominate; noradrenergic effects become more prominent with greater exposure, but there is no single universal dose at which a switch occurs. The pharmacology provides a plausible basis for antidepressant activity and for adverse effects involving autonomic activation, sweating, blood pressure, sexual function and serotonergic toxicity. It does not establish causality for an individual report. [1,2]
Venlafaxine undergoes hepatic metabolism, including CYP2D6-mediated formation of O-desmethylvenlafaxine. Renal elimination of parent drug and metabolites means impaired renal function can change exposure. Hepatic dysfunction, interacting drugs, variable metabolic capacity and age-related physiological changes also matter. Dose adjustment and administration decisions must follow the actual formulation's current product information rather than a generic class rule. [1,2]
Formulation and discontinuation
Extended-release delivery can reduce peak-to-trough variation compared with immediate-release administration, but does not eliminate adverse reactions or withdrawal phenomena. Abrupt cessation, rapid tapering or missed doses may be followed by dizziness, sensory disturbances, nausea, sleep disruption, anxiety and other symptoms. In a patient whose symptoms begin shortly after a missed dose, the temporal relationship may support a discontinuation hypothesis; relapse of depression, a new medical illness or another drug effect must still be assessed. [1,2]
Discontinuation syndrome is not proof of dependence in the same sense as substance-use disorder, nor should every symptom following dose reduction automatically be attributed to withdrawal. The clinical record should distinguish the last confirmed dose, actual dispensing history, intended taper, symptom onset, reinstatement and subsequent evolution. The UK SmPC recognises that some discontinuation reactions can be severe or prolonged, and that tapering may need to be individualised. [2]
Evidence of benefit and its boundaries
Acute depression and continuation therapy
Placebo-controlled studies established efficacy in depression, while active-comparator trials inform relative treatment performance in particular populations. In the PREVENT programme, 1,096 patients with recurrent unipolar major depression entered an initial randomised comparison of venlafaxine extended release and fluoxetine. In the acute phase, response rates were 79% in both arms and remission rates 49% and 50%, respectively; the reported continuation outcomes were also broadly similar. This study does not show superiority of venlafaxine over fluoxetine in that trial population. [5]
The PREVENT design is instructive because acute response, continuation of remission and prevention of later recurrence are different endpoints. A treatment that is effective for acute symptoms is not automatically proven to prevent recurrence indefinitely, and a maintenance benefit in selected responders cannot be applied without qualification to everyone starting treatment.
Recurrence prevention and selection effects
In the first PREVENT maintenance year, selected patients who had responded to prior venlafaxine treatment were randomised to continued venlafaxine or placebo. The estimated cumulative recurrence probabilities were 23.1% and 42.0%, respectively, over 12 months in the reported efficacy-evaluable groups. The result supports maintenance efficacy among prior responders, but the enrichment design limits extrapolation to untreated or treatment-resistant populations. [6]
The second-year analysis likewise favoured venlafaxine over placebo in a smaller selected group; reported 12-month recurrence probabilities were 8.0% versus 44.8%, with 43 and 40 patients in the respective comparison groups. These are not rates of treatment-emergent adverse reactions, nor are the two maintenance years interchangeable independent replications. [7]
Anxiety indications and evidence interpretation
The US extended-release label summarises placebo-controlled studies in GAD, social anxiety disorder and panic disorder. These indications involve different symptom scales, baseline risks, follow-up periods and concomitant treatments. A pooled safety percentage across indications should not be treated as an indication-specific incidence estimate. The clinician must also weigh symptom burden, functional improvement, tolerability, previous response and alternatives when deciding whether continuation remains justified. [1]
A useful evidence review therefore separates the treatment question (does the drug improve a specified clinical endpoint?) from the safety question (what adverse effects were ascertained, in whom and for how long?). The original trial denominator, dose range, duration and reason for discontinuation should accompany every quantitative comparison.
Safety profile: mechanisms, clinical phenotypes and risk management
Blood pressure and autonomic effects
Venlafaxine can increase blood pressure; the US label specifically advises controlling pre-existing hypertension before initiation and monitoring during treatment. Sustained elevation should be distinguished from an isolated measurement obtained during pain, panic, acute illness or medication change. A case review needs baseline and serial readings, dose increases, co-prescribed sympathomimetics and clinical management. [1]
Noradrenergic pharmacology makes dose and exposure plausible modifiers, but does not establish a precise risk threshold for every patient. In observational comparisons, indication severity and concomitant drugs can confound apparent dose–response relationships. A signal evaluation should define hypertension consistently, consider person-time and avoid interpreting spontaneous reports as incidence.
Serotonin syndrome and interactions
Serotonin syndrome is a potentially serious clinical syndrome that may follow excess serotonergic activity, especially with interacting agents. Clinical assessment combines mental-status changes, autonomic findings, neuromuscular abnormalities, exposure chronology and alternative diagnoses. The US label includes serotonin syndrome among major warnings and contraindicates relevant monoamine oxidase inhibitor combinations. [1]
Concomitant serotonergic antidepressants, certain analgesics and other medicines may increase concern, but a mere drug–drug interaction alert is not proof that a reported syndrome meets diagnostic criteria. Record the complete regimen, doses, recent additions or withdrawals, examination findings, temperature, reflexes, clonus, laboratory evaluation and treatment course. Never deliberately rechallenge to establish a suspected severe reaction.
Bleeding and platelet effects
Serotonin reuptake inhibition can alter platelet serotonin handling, providing a biologically plausible contribution to bleeding risk. The USPI warns of increased bleeding, particularly with drugs that affect haemostasis. The clinically relevant question is not whether the patient received venlafaxine alone, but whether aspirin, non-steroidal anti-inflammatory drugs, anticoagulants, thrombocytopenia, ulcer disease or a procedure also contributed. [1]
For a major haemorrhage, document anatomical site, imaging or endoscopy, haemoglobin change, transfusion, coagulation parameters, antithrombotic indication and interruption chronology. Minor bruising and life-threatening gastrointestinal bleeding must not be merged into an undifferentiated severity category.
Suicidality and psychiatric activation
The US boxed warning describes increased suicidal thoughts and behaviours in younger patients treated with antidepressants, particularly early in treatment and after dose changes. A reported suicidal event demands urgent clinical attention, but temporal association alone cannot separate drug contribution from underlying depressive illness, emerging agitation, mixed affective states, psychosocial stressors or other exposures. [1]
Pharmacovigilance documentation should preserve the reporter's account, age, baseline psychiatric history, prior attempts, event timing, dose changes, co-therapies and outcome. Mania or hypomania may emerge during antidepressant treatment, especially where bipolar vulnerability has not been recognised. The clinical diagnosis and seriousness classification should not be inferred from a single symptom such as insomnia.
Discontinuation symptoms versus relapse
Discontinuation is a central venlafaxine safety problem because its symptoms may be mistaken for recurrence of the underlying disorder or a new neurological condition. Dizziness, sensory disturbances, insomnia, nausea and anxiety can occur after abrupt cessation or dose reduction. Some symptoms overlap with depression or anxiety relapse; chronology and symptom quality are therefore essential. [1,2]
A useful assessment records the exact formulation and last dose, the taper schedule, missed doses, onset interval, prior discontinuation experiences, reintroduction if clinically undertaken and the time course of recovery. A rapid symptomatic improvement after reinstatement may support withdrawal, but is not an experimental proof of causality. Regulatory labelling recommends gradual dose reduction, with individualisation according to tolerability. [1,2]
Hyponatraemia, seizures, ocular and pulmonary events
The US label warns of hyponatraemia, seizures, angle-closure glaucoma and interstitial lung disease/eosinophilic pneumonia. These are distinct syndromes requiring specific confirmation and differential diagnosis rather than a generic 'neurological adverse event' category. For hyponatraemia, capture serum sodium, volume status, other implicated medicines and comorbidities; for a seizure, capture neurological history, metabolic triggers and overdose possibility. [1]
Acute ocular pain and visual disturbance warrant consideration of angle closure in a susceptible patient, while a pulmonary report requires imaging, oxygenation, infectious work-up and other exposures. A warning does not establish that the product caused every clinically similar event. Clinical management should follow urgent local assessment where appropriate, independently of pharmacovigilance reporting.
Sexual dysfunction and longer-term tolerability
Sexual adverse reactions can substantially affect adherence and quality of life but may be underreported without direct, respectful questioning. Depression itself and other drugs can also impair sexual function. The US clinical-trial table reports abnormal ejaculation, erectile dysfunction and reduced libido among observed reactions, with sex-specific denominators for some terms. These rates are not universal prevalence estimates. [1]
A meaningful case records baseline sexual function, onset relative to treatment, persistence after dose modification or cessation, concomitant medication and the patient's own description. Avoid assuming that a symptom not spontaneously mentioned was absent.
Product-specific listedness and jurisdictional comparison
Named sources and scope
This public-label assessment uses the US Proficient Rx LP repackaged venlafaxine hydrochloride extended-release capsules DailyMed label, whose displayed adverse-reaction section is dated June 2022, and the UK Venlafaxine SUN Pharma XL 150 mg prolonged-release tablets SmPC as accessible on the electronic Medicines Compendium, accessed 7 November 2026. [1,2] The UK document is not an EU-authorised SmPC, and the dosage form is a prolonged-release tablet rather than a capsule. Consequently the comparison is informative but is not a same-formulation US/EU listedness determination. The UK document's electronic Medicines Compendium header records an update on 5 June 2025; this is the date of the named UK SmPC, not evidence that it is the latest label in every jurisdiction.
The United States and United Kingdom differ in their authorised indications, formulation-specific instructions and presentation of adverse-reaction frequencies. For any individual case, the governing local label or approved reference safety information, not this illustrative comparison, determines the applicable assessment.
Explicit adverse-reaction comparison
| Event or dimension | US extended-release capsule label | UK SUN Pharma XL tablet SmPC | Interpretation |
|---|---|---|---|
| Nausea | Listed in section 6.1 trial table: 30% of venlafaxine recipients versus 11.8% placebo in pooled short-term studies | Listed as very common in section 4.8 | Both documents identify the reaction, but frequency presentations differ |
| Dry mouth | Listed: 14.8% versus 5.3% placebo in the same pooled US table | Very common | Same general phenotype, different frequency framework |
| Sweating | Listed: 11.4% versus 2.9% placebo | Very common, including night sweats | Terms should be preserved as written |
| Hypertension | Listed in US section 6.1 table: 3.4% versus 2.6% placebo; separately addressed in section 5.3 | Addressed in SmPC adverse reactions and warnings; exact frequency term requires direct section-4.8 extraction | Warning status is not equivalent to frequency classification |
| Discontinuation symptoms | Addressed in US sections 5.7 and 6; multiple symptoms described | Discussed in sections 4.2, 4.4 and 4.8 | Record specific symptom terms, not only a syndrome umbrella |
| Serotonin syndrome | Explicit warning in US section 5.2 | UK SmPC contains serotonergic toxicity precautions | Do not assume identical tabular listedness from warning text |
| Suicidal thoughts and behaviours | US boxed warning and clinical precautions | UK psychiatric safety precautions | Underlying disease and treatment effects require case-specific assessment |
The US percentages come from the named label's short-term placebo-controlled database, with 3,558 venlafaxine and 2,197 placebo recipients across several indications. They must not be described as population incidence or compared directly with UK frequency categories. The UK SmPC's 'very common' classification is a regulatory frequency band, not a trial-arm percentage. [1,2]
Listedness conclusion: nausea, dry mouth and sweating are explicitly listed in the assessed US clinical-trial table and the assessed UK section-4.8 adverse-reaction presentation. Hypertension is explicitly listed in the US table and warned about in both jurisdictions; exact UK frequency and every other event's tabular status must be checked against the current named SmPC before case-specific listedness is asserted. No statement that an event is unlisted follows from an absent entry in this selected comparison.
This exercise does not establish company-core listedness, expectedness against the reference safety information applicable to a particular case, causality, seriousness or regulatory reportability. A UK SmPC cannot be silently substituted for an EU SmPC, and an extended-release tablet cannot be assumed interchangeable with an extended-release capsule for all labelling purposes.
EU member-state SmPC verification: Spanish SUN prolonged-release tablets
A second, jurisdictionally distinct comparison is available from the Spanish Agency of Medicines and Medical Devices (AEMPS), through its CIMA database: Venlafaxina Sun 75 mg and 150 mg prolonged-release tablets, section 4.8, accessed 7 November 2026. This is Spanish nationally authorised product information for the same active substance and broad release/dosage-form category as the UK SUN tablet, not an EMA centrally authorised product or an exact matched brand/manufacturer comparison with US Effexor XR capsules. The source is the regulator-hosted current record consulted on that date; a precise revision date was not independently established from the accessible page. [8]
The Spanish section 4.8 expressly identifies nausea, dry mouth, headache and sweating (including night sweats) as very common (at least 1 in 10) in its safety-profile summary. Its system-organ-class table also lists hypertension as common (at least 1 in 100 and less than 1 in 10), as distinct from hypotension and orthostatic hypotension. The table includes serotonin syndrome, seizures, QT prolongation/ventricular arrhythmias and gastrointestinal haemorrhage in other frequency categories. Its post-marketing footnotes and category-specific caveats matter: a term's appearance in the adverse-reaction table does not establish a numerically estimable incidence for a spontaneous-report-derived event. [8]
| Explicit term or safety dimension | US Effexor XR originator label, revised August 2022 | Spanish Venlafaxina Sun prolonged-release tablet SmPC, section 4.8 | Listedness interpretation |
|---|---|---|---|
| Nausea | Section 6.1 Table 9: 30.0% vs 11.8% placebo | Very common | Listed in both assessed documents; denominators differ |
| Dry mouth | Table 9: 14.8% vs 5.3% | Very common | Listed in both |
| Sweating, including night sweats | Table 9: 11.4% vs 2.9% | Very common | Listed in both; retain exact coded term |
| Hypertension | Table 9: 3.4% vs 2.6%; section 5.3 warning | Common | Listed in both, but US trial percentage is not the EU frequency-band estimate |
| Serotonin syndrome | Section 5.2 warning | Explicit section-4.8 adverse-reaction entry | Do not infer that the US warning has the same statistical provenance as the EU table |
| Suicidality | Boxed warning | Suicidal ideation/behaviour in section 4.8 with footnote on reports during treatment or immediately after stopping | Preserve indication, age and clinical context; tabular placement is not proof of individual causation |
The US originator source in this table is Wyeth Pharmaceuticals' Effexor XR extended-release capsules, DailyMed, revised August 2022 and accessed 7 November 2026, rather than the separately referenced Proficient Rx repackaged label. The displayed originator Table 9 includes 3,558 active-treated and 2,197 placebo-treated participants across short-term studies in multiple indications. Its sections 5 and 6 have different evidentiary functions. The existence of newer US labels for other venlafaxine products would not automatically update this named originator version. [9]
Updated US branded label: 2023 Viatris Effexor XR
An additional branded Effexor XR extended-release capsule SPL is listed by DailyMed under Viatris Specialty LLC, updated 15 August 2023 (revised 8/2023), accessed 8 November 2026. Its section 6.1 Table 9 retains the pooled short-term study denominator of 3,558 treated and 2,197 placebo recipients and the listed adverse reactions nausea (30.0% versus 11.8%), dry mouth (14.8% versus 5.3%), sweating including night sweats (11.4% versus 2.9%) and hypertension (3.4% versus 2.6%). This independently confirms those specific figures against a later dated branded US label, rather than relying solely on the 2022 Wyeth document. [10]
The 2023 Viatris document identifies changes to sections 5.2 (serotonin syndrome) and 5.4 (bleeding) in August 2023. Its sections 5 and 6 must still be read separately: a warning does not by itself establish a trial-table adverse-reaction frequency. This is a dated comparison of specified SPL records, not proof that no newer US labelling exists. Before a case-specific decision, retrieve the applicable marketed product's current SPL and confirm its effective revision. [10]
This side-by-side extraction resolves the earlier absence of any EU member-state adverse-reaction table, but does not replace verification of the exact nationally applicable reference information for a real case. The Spanish regulator's HTML table has some flattened columns in text rendering, so only the frequency categories directly supported by its readable entries and summary are asserted above. In particular, a missing term from this selected table should never be labelled unlisted without full source review.
Special populations and clinical context
In renal or hepatic impairment, reduced clearance may increase exposure, and the product-specific label gives adjustment instructions. Older patients may have multiple interacting medicines and greater susceptibility to hyponatraemia or falls. Pregnancy and lactation require a benefit-risk assessment based on the current label and individual clinical circumstances rather than a categorical statement that all antidepressant exposure is harmful. [1,2]
Children and adolescents warrant particular caution because of suicidality warnings and differences in approved use. A paediatric clinical-study adverse event is not evidence that the product is authorised for that indication in that country. The exact local indication and age restrictions should be checked independently of pharmacovigilance case classification.
Practical pharmacovigilance: from report to evidence
Intake and source preservation
A high-quality venlafaxine report identifies the patient and reporter according to the applicable reporting framework and preserves the original source account. Clinically useful details include indication, age, formulation, manufacturer if known, strength, actual dosing schedule, start and stop dates, missed doses, interacting medicines, event onset, objective findings, interventions and outcome. Do not silently convert a reporter's 'electric shock feeling' into a confirmed neurological diagnosis; preserve verbatim wording alongside the coded term.
| Suspected event | High-value follow-up | Important competing explanations |
|---|---|---|
| Discontinuation syndrome | Last actual dose, taper, refill gap, sensory symptoms, reinstatement | Relapse, vestibular disorder, intercurrent illness |
| Hypertension | Serial BP, dose changes, other pressor drugs | Baseline hypertension, pain, acute anxiety |
| Serotonin syndrome | Clonus, reflexes, temperature, recent serotonergic additions | Infection, neuroleptic malignant syndrome, intoxication |
| Bleeding | Site, severity, antithrombotics, endoscopy/imaging | Ulcer disease, trauma, coagulation disorder |
| Hyponatraemia | Sodium trend, fluid status, diuretics, renal function | SIADH from other causes, volume depletion |
| Suicidal behaviour | Exact event, psychiatric history, treatment changes, clinical outcome | Illness course, psychosocial triggers, other drugs |
Causality, seriousness, expectedness and reporting
These decisions answer different questions. Clinical causality asks whether venlafaxine plausibly contributed to the event. Seriousness is defined by the applicable regulatory criteria, not by the intensity of symptoms alone. Listedness compares a specific event against a specific version of reference product information; expectedness for reporting may use different approved reference safety information. Reportability and timelines follow the applicable law and procedures, not an article's educational table.
For example, a patient with severe dizziness after an unplanned interruption might have a plausible discontinuation reaction, but whether the case is serious depends on its consequences and regulatory criteria. A different patient hospitalised with hyponatraemia needs an assessment of serum sodium, clinical severity, other causes and all co-medications; the existence of a label warning does not close the causality question.
From individual cases to signals
A rising number of reports of withdrawal symptoms may reflect increased prescribing, awareness after a public communication, changed reporting routes or a true shift in risk. A sound signal assessment defines a case series, removes duplicates, evaluates the time relationship and missing-dose patterns, and triangulates spontaneous reports with trials, pharmacoepidemiology and medication-use data. Reports alone cannot provide an incidence denominator.
Discontinuation-related events pose a particular ascertainment problem. A patient who stops treatment may leave an on-treatment cohort precisely because of intolerance. If only continuing users are observed, subsequent safety estimates may underrepresent early adverse reactions. Exposure windows and follow-up after stopping should therefore be explicit.
Illustrative case-to-signal exercise
Consider a hypothetical outpatient whose extended-release venlafaxine prescription was delayed over a weekend. The patient reports dizziness, nausea, disturbed sleep and sensory shocks, followed by improvement after treatment is resumed under clinical supervision. The assessment should establish the actual missed-dose interval, the prior stable dose, whether the pharmacy dispensed a different release formulation, other recent drug changes and alternative neurological causes. The report may support a withdrawal-related hypothesis; it is not a controlled rechallenge experiment.
If several similar reports arise from the same pharmacy network, the safety team should check for a dispensing or supply problem rather than treating every report as independent proof of an intrinsic new pharmacological risk. Reconciliation with medical information, quality complaints and distribution records may be informative. Record the evidence for the hypothesis, competing explanations and the rationale for any proposed corrective action.
Overdose, QT risk and postpartum haemorrhage: three distinct assessment pathways
A venlafaxine overdose report should capture the estimated ingested dose, formulation, time of ingestion, co-ingestants, serial observations, electrocardiographic findings, seizures and interventions. The Spanish AEMPS SmPC describes serious and fatal overdose reports, frequently with other medicines or alcohol, and identifies post-marketing QTc prolongation and ventricular arrhythmias, particularly in overdose or in patients with additional risk factors. These observations justify careful clinical assessment but do not make every QT change attributable to venlafaxine. [8]
A therapeutic-dose arrhythmia report requires a different analysis: documented QTc and correction method, baseline ECG if available, potassium and magnesium, structural heart disease, concomitant QT-prolonging medicines and renal or hepatic impairment. Pooling deliberate overdoses with routine therapeutic exposure can produce a misleading signal. The Spanish SmPC's section 4.8 contains QT-related terms, but the section 4.4 precaution and post-marketing provenance must be retained when communicating the evidence. [8]
Postpartum haemorrhage is another context-specific safety question. The Spanish product information addresses increased postpartum bleeding risk for the SSRI/SNRI therapeutic class and includes a postpartum-haemorrhage term with a class-evidence footnote. That is not a product-specific trial incidence estimate. A useful case captures timing of venlafaxine exposure during pregnancy and delivery, quantified blood loss where available, uterine atony, obstetric procedures, placental factors, anticoagulants and the newborn outcome separately. Causality cannot be inferred from delivery-time exposure alone. [8]
These examples show why label location, evidence origin and clinical context belong in the same assessment. A warning, a tabulated post-marketing reaction and a class-level precaution can all be relevant while supporting different strengths and kinds of conclusion. The exact national product information must be rechecked when the case is assessed; this article is not an approved reference-safety-information substitute.
Risk minimisation and governance
Risk minimisation can include careful medication reconciliation, blood-pressure monitoring, explanation of discontinuation symptoms and an individualised taper when treatment is being stopped. Distinguish a product-label instruction from a local clinical protocol or an organisation's recommended control. Effectiveness cannot be established merely by distributing an educational leaflet; appropriate indicators include correct dosing instructions, recognition of warning symptoms and fewer preventable interruption errors.
Inspection-ready records preserve the source report, case versions, follow-up attempts, coding decisions, medical review, reference-information version, submission history and any aggregate signal decisions. A failure to obtain follow-up information should be documented, not replaced with assumed normal results.
Figure assessment
A mechanism diagram was considered for serotonin and noradrenaline reuptake, and a taper-to-withdrawal timeline was considered for discontinuation. Neither would add reliable decision detail beyond the two-column clinical explanations and event-specific follow-up matrix above without introducing an oversimplified dose threshold or a misleading universal withdrawal timeline. No SVG is therefore proposed for this source version. Reassess if a validated pharmacokinetic figure with actual formulation-specific data becomes available.
Key takeaways
Venlafaxine's safety profile is inseparable from formulation, dose history, co-medications and treatment interruptions. Important surveillance topics include blood-pressure elevation, serotonin syndrome, bleeding, suicidality, hyponatraemia, sexual dysfunction and discontinuation reactions. Regulatory listedness is product-, jurisdiction-, section- and version-specific; a warning or pooled trial frequency must not be mistaken for a universal incidence estimate. Good pharmacovigilance retains the clinical chronology and uncertainty while distinguishing the patient's treatment needs from the regulatory reporting decision.
References
- Proficient Rx LP (repackaged product; source NDC 65862-528). Venlafaxine hydrochloride extended-release capsules: US prescribing information, DailyMed, updated 1 June 2022. Accessed 7 November 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18e77a42-6552-4042-9ed3-046c94f4f921
- Ranbaxy (UK) Limited, a Sun Pharmaceutical Company. Venlafaxine SUN Pharma XL 150 mg prolonged-release tablets: UK Summary of Product Characteristics, electronic Medicines Compendium, last updated 5 June 2025. Accessed 7 November 2026. https://www.medicines.org.uk/emc/product/5349/smpc
- Wyeth historical product disclosure, US SEC filing (2003), Effexor and Effexor XR chronology. https://www.sec.gov/Archives/edgar/data/885590/000104746903019357/a2111243z20-f.htm
- FDA historical approval archive. Venlafaxine XR, 20 October 1997. OHSU digital collections. https://digitalcollections.ohsu.edu/record/3330
- Keller MB et al. PREVENT: acute and continuation phases. Biol Psychiatry. 2007;62:1371–1379. doi:10.1016/j.biopsych.2007.04.040. https://pubmed.ncbi.nlm.nih.gov/17825800/
- Kocsis JH et al. PREVENT: one-year maintenance phase. J Clin Psychiatry. 2007;68:1014–1023. doi:10.4088/JCP.v68n0706. https://pubmed.ncbi.nlm.nih.gov/17685736/
- Keller MB et al. PREVENT: second-year and combined maintenance results. J Clin Psychiatry. 2007;68:1246–1256. doi:10.4088/JCP.v68n0812. https://pubmed.ncbi.nlm.nih.gov/17854250/
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Venlafaxina Sun 75 mg and 150 mg comprimidos de liberación prolongada, ficha técnica, sections 4.1–4.8. CIMA regulator-hosted product information. Accessed 7 November 2026; exact document revision date not independently verified. https://cima.aemps.es/cima/dochtml/ft/76604/FT_76604.html
- Wyeth Pharmaceuticals LLC (Pfizer). Effexor XR (venlafaxine hydrochloride) extended-release capsules, US prescribing information, revised August 2022, sections 5 and 6. DailyMed. Accessed 7 November 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53c3e7ac-1852-4d70-d2b6-4fca819acf26
- Viatris Specialty LLC. Effexor XR (venlafaxine hydrochloride) extended-release capsules, US prescribing information, updated 15 August 2023, revised 8/2023, sections 5.2, 5.4 and 6.1. DailyMed. Accessed 8 November 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c848a5d8-ba94-4c84-80e3-0bf35fb8e32e
Regulatory Note
This educational review does not replace current local prescribing information, approved reference safety information, clinical judgement or the applicable reporting legislation. The UK SmPC is not an EU SmPC; a separate Spanish EU member-state SmPC is assessed here. The US capsule and Spanish/UK tablets are not exact matched-formulation comparisons. Verify the actual product, jurisdiction, document version and event term before a real listedness or expectedness determination.